IST5-002 was demonstrated to bind to the SH2 domain of STAT5B, to inhibit P-Y-STAT5 and to reduce the growth and viability of sensitive and IM-resistant CML and Ph+ALL cell lines [321]. The gene discussed is STAT5A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.